X4 Pharmaceuticals Inc (XFOR)
0.9031
0.00 (0.00%)
USD |
NASDAQ |
May 24, 16:00
0.9012
0.00 (0.00%)
After-Hours: 20:00
X4 Pharmaceuticals Net Income (Quarterly): -51.77M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -51.77M |
| December 31, 2023 | -19.13M |
| September 30, 2023 | -2.305M |
| June 30, 2023 | -55.71M |
| March 31, 2023 | -24.02M |
| December 31, 2022 | -29.10M |
| September 30, 2022 | -21.59M |
| June 30, 2022 | -21.21M |
| March 31, 2022 | -21.96M |
| December 31, 2021 | -30.21M |
| September 30, 2021 | -20.18M |
| June 30, 2021 | -19.64M |
| March 31, 2021 | -18.68M |
| December 31, 2020 | -18.40M |
| September 30, 2020 | -17.45M |
| Date | Value |
|---|---|
| June 30, 2020 | -15.14M |
| March 31, 2020 | -11.14M |
| December 31, 2019 | -10.84M |
| September 30, 2019 | -17.71M |
| June 30, 2019 | -13.38M |
| March 31, 2019 | -10.87M |
| December 31, 2018 | 0.378M |
| September 30, 2018 | -10.90M |
| June 30, 2018 | -12.13M |
| March 31, 2018 | -10.63M |
| December 31, 2017 | -11.19M |
| September 30, 2017 | -11.60M |
| June 30, 2017 | -5.705M |
| March 31, 2017 | -5.385M |
| December 31, 2016 | -5.321M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-55.71M
Minimum
Jun 2023
-2.305M
Maximum
Sep 2023
-21.98M
Average
-19.38M
Median
Net Income (Quarterly) Benchmarks
| Phio Pharmaceuticals Corp | -2.154M |
| Ocular Therapeutix Inc | -64.85M |
| Alpine Immune Sciences Inc (DELISTED) | -17.92M |
| Scholar Rock Holding Corp | -56.85M |
| RAPT Therapeutics Inc | -30.52M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 37.29M |
| EPS Diluted (Quarterly) | -0.26 |
| Enterprise Value | 125.62M |
| Earnings Yield | -76.40% |